Shire -4.4% after Vyvanse misses primary endpoints in two phase-3 studies

|About: Shire PLC (SHPG)|By:, SA News Editor

Shire (SHPG) -4.4% AH after announcing that results from two Phase 3 studies for Vyvanse capsules as an adjunctive treatment for adults with major depressive disorder did not meet the primary efficacy endpoint in either study, and Shire will no longer pursue the clinical development program.

Shire says it we will file later this year with the FDA for a new indication for Vyvanse in binge eating disorder in adults; Vyvanse already is approved for the treatment of ADHD in the U.S., Canada, Australia, Brazil and several European countries.